FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer
The Food and Drug Administration (FDA) granted accelerated approval to sacituzumab govitecan-hziy for adult patients…
Browsing: metastatic triple negative breast cancer
New ‘smart drug’ shows promise for metastatic triple-negative breast cancer
A new “smart drug” has shown promise for women with metastatic triple-negative breast cancer, based…
‘Liquid biopsy’ can help predict outcomes in metastatic triple-negative breast cancer
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood…